Octreotide vs AHK-Cu
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Octreotide
Octreotide (Sandostatin) is a synthetic somatostatin analog FDA-approved for acromegaly, carcinoid tumors, and VIPomas. It inhibits growth hormone and various GI hormones.
Full details →AHK-Cu
AHK-Cu (Copper Tripeptide-3, Alanine-Histidine-Lysine Copper) is a copper peptide similar to GHK-Cu but with different properties. It's used for hair growth and skin rejuvenation applications.
Full details →Side-by-Side Comparison
| Aspect | Octreotide | AHK-Cu |
|---|---|---|
| Mechanism | Binds to somatostatin receptors (primarily SSTR2 and SSTR5) to inhibit GH, glucagon, insulin, and gastric secretions. Reduces blood flow to GI tract and inhibits tumor hormone secretion. | The copper-binding tripeptide stimulates collagen synthesis and may promote hair follicle enlargement. Works similarly to GHK-Cu but may have distinct receptor interactions. |
| Typical Dosage | Varies by indication. Acromegaly: 50-100mcg three times daily initially, up to 500mcg TID. LAR (long-acting): 20-30mg IM every 4 weeks. | Topical: 0.5-2% concentration in serums for skin or scalp applications. Often combined with other growth factors for hair formulations. |
| Administration | Subcutaneous injection for immediate-release (between meals). Intramuscular for LAR depot form. Requires monitoring of gallbladder, glucose, and thyroid. | Topical application to skin or scalp. Can be used with microneedling for enhanced penetration. May cause temporary blue-green tint at high concentrations. |
| Side Effects | GI effects (diarrhea, nausea, abdominal pain), gallstones (up to 25% of long-term users), injection site reactions, and blood glucose changes. | Generally well-tolerated. May cause skin irritation in sensitive individuals. Temporary discoloration possible. |
| Best For |